COPD pharmacological management is increasingly shaped by precision stratification based on symptom burden, exacerbation history, and blood eosinophil count. Current GOLD guidelines reinforce the primacy of dual long-acting bronchodilation, a long-acting muscarinic antagonist (LAMA) plus long-acting beta-2 agonist (LABA), in symptomatic patients.

Extensive clinical evidence demonstrates that LAMA/LABA combinations reduce annual exacerbation rates, delay time to first exacerbation, and produce superior post-bronchodilator FEV₁ improvements compared to ICS-containing dual regimens in patients without qualifying eosinophil counts (≥300 cells/µL) or exacerbation history thresholds. Despite this evidence, real-world prescribing analyses reveal substantial LABA/ICS overuse in COPD patients who do not meet evidence-based criteria, exposing them to unnecessary pneumonia risk and metabolic adverse effects. GOLD 2023 recommends LAMA/LABA as preferred initial combination therapy, with ICS reserved for specific eosinophilic or exacerbation-history criteria. Pulmonologists, respiratory specialists, and primary care physicians managing COPD will benefit from peer discussion of LAMA/LABA optimization, ICS incorporation criteria, and evidence-based de-escalation approaches.

How do you determine which COPD patients are candidates for ICS-containing therapy versus LAMA/LABA dual bronchodilation, and what role do blood eosinophil counts and exacerbation history play? What challenges do you encounter when de-escalating LABA/ICS regimens in stable COPD patients who do not meet evidence-based criteria, and how do you navigate patient resistance?